Table 1 Long-COVID outpatient demographics and clinical data
Initial infection variable | Outpatients (n = 22) |
|---|---|
Age (yrs), median (IQR) | 61.0 (20.5) |
Male sex, no. (%) | 12 (54.5) |
Diagnostic test: PCR, serology, no. (%) | 22 (100.0) |
Vaccination status at infection, no. (%) | 2 (9.1) |
Hospitalization, no. (%) | |
Ward | 7 (30.4) |
ICU | 1 (4.3) |
Comorbidities, no. (%) | |
Diabetes | 6 (27.3) |
Hypertension | 8 (36.4) |
Coronary artery/heart disease | 2 (9.1) |
Chronic/congestive heart failure | 0 (0.0) |
Chronic kidney disease | 0 (0.0) |
Cancer | 1 (4.5) |
COPD | 0 (0.0) |
Asthma | 4 (18.2) |
Presenting symptoms at infection, no. (%) | |
Fever | 16 (72.7) |
Cough | 17 (77.3) |
Anosmia/Ageusia | 13 (59.1) |
Pharyngitis | 8 (36.4) |
Headache | 14 (63.6) |
Confusion/Memory | 2 (9.1) |
Myalgias | 13 (59.1) |
Dyspnea | 16 (72.7) |
Chest pain | 8 (36.4) |
Nausea/Vomiting/Diarrhea | 11 (50.0) |
Interventions at infection, no. (%) | |
Steroids | 6 (27.3) |
Remdesivir | 0 (0.0) |
Tocilizumab | 1 (4.5) |
Long-COVID Clinic Variables | |
Follow up, days from infection onset, median (IQR) | 101.5 (45.5) |
Lingering symptoms at follow up, no. (%) | |
Respiratory | 16 (72.7) |
Cardiovascular | 6 (27.3) |
Neurologic | 8 (36.4) |
Musculoskeletal | 0 (0.0) |
Gastro-Intestinal | 3 (13.6) |
Psychiatric | 1 (4.5) |
Cutaneous | 0 (0.0) |
Balance | 0 (0.0) |
Chest pain | 4 (18.2) |
Concentration | 0 (0.0) |
Cough | 2 (9.1) |
Dyspnea | 16 (72.7) |
Fatigue | 11 (50.0) |
Headache | 2 (9.1) |
Low mood | 1 (4.5) |
Anxiety | 1 (4.5) |
Memory | 6 (27.3) |
Nausea | 1 (4.5) |
Palpitations | 1 (4.5) |
Paresthesia | 1 (4.5) |
Smell/taste | 2 (9.1) |
Word finding | 1 (4.5) |
Non-specific | 11 (50.0) |
Laboratories at follow up, median (IQR) | |
White blood cell count | 7.1 (1.9) |
Neutrophils | 4.5 (1.5) |
Lymphocytes | 2.0 (0.7) |
Hemoglobin | 139.5 (24.8) |
Platelets | 239.5 (64.2) |
C-Reactive Protein (CRP) | 1.8 (3.5) |
Ferritin | 76.0 (118.8) |
Lactate Dehydrogenase (LDH) | 206.0 (39.0) |
Alanine Aminotransferase (ALT) | 20.0 (11.2) |
Interventions at follow up, no. (%) | |
Budesonide | 1 (4.5) |
Anticoagulant | 1 (4.5) |
Budesonide/Formoterol | 10 (45.5) |
Salbutamol | 3 (13.6) |
Furosemide | 1 (4.5) |
Nasal spray | 2 (9.1) |
Oxygen | 2 (9.1) |
Physiotherapy | 4 (18.2) |
None | 8 (36.4) |